Nucleus Genomics, a clinical-grade whole-genome sequencing platform, has received a strategic investment from Samsung Next, building on a $14 million Series A led by Founders Fund and Seven Seven Six with participation from Neo and Balaji Srinivasan.
Nucleus offers a $499 physician-ordered test that sequences approximately 100% of a patient’s DNA, covering over 2,000 diseases and conditions through a CLIA-certified, CAP-accredited U.S. lab. The company recently acquired Cambrean, an AI-powered wearable health platform, to combine continuous biometric data with genetic baselines for more personalized health insights.
Samsung Next said Nucleus stood out for “its scientific rigor, delivering validated clinical-grade results rather than entertainment-grade ancestry estimates” and its potential as the genetic baseline layer that contextualizes data from wearables and health sensors.
The investment signals a broader repositioning for Nucleus. The company first drew attention – and controversy – in the fertility space with its Nucleus Embryo product, which launched in 2025 in partnership with Genomic Prediction. The software went well beyond standard embryo screening for chromosomal abnormalities, allowing IVF patients to compare embryos based on traits including appearance, cognitive ability, and mental health characteristics – raising fundamental questions about where genetic medicine should draw ethical lines.
With this latest investment and the Cambrean acquisition, Nucleus appears to be broadening its positioning from embryo optimization into a general preventive health genomics platform – with fertility as one use case among several that now include partnerships with Bryan Johnson’s Don’t Die longevity program and both U.S. and international fertility clinics.
